ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients Key updates With the clearance of the investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA), ProQR can now start clinical development of QR-110 in Leber’s...

ProQR to Present at the Deutsche Bank Health Care Conference LEIDEN, the Netherlands, April 20, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that Gerard Platenburg, Chief Innovation Officer, will present at the 42nd Annual...

ProQR Announces Annual Meeting of Shareholders LEIDEN, the Netherlands, April 10, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Annual General Meeting of Shareholders will be held on Wednesday, May 10,...

ProQR Announces the Grant of two Key Patents, protecting QR-010 for Cystic Fibrosis in the US and EU Key Updates ProQR received notice of grant for 2 key patents protecting QR-010 for CF in the US and EU until at least July 2033QR-010 is currently being studied in 64 homozygous F508del patients in a...